Advancements in Subcutaneous Cancer Treatments and Molecular Targets

This chapter covers the FDA approval of subcutaneous daratumumab, highlighting its benefits over IV administration, before delving into MET exon-14 skipping mutations and the approval of capmatinib for treating specific lung cancers. It emphasizes the efficacy and safety considerations of these treatments, including patient monitoring and their integration into oncologic regimens.